Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 3;149(1):12.
doi: 10.1007/s00401-025-02849-8.

IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread

Affiliations

IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread

Felix Hinz et al. Acta Neuropathol. .

Abstract

IDH-mutant astrocytomas are diffuse gliomas that are defined by characteristic mutations in IDH1 or IDH2 and do not have complete 1p/19q co-deletion. The established grading criteria include histological features of brisk mitotic activity (grade 3) and necrosis and/or microvascular proliferation (grade 4). In addition, homozygous deletion of the CDKN2A/B locus has recently been implemented as a molecular marker for grade 4 IDH-mutant astrocytomas. Here, we describe a subgroup of high-grade IDH-mutant astrocytomas characterised by a primitive neuronal component based on histology and a distinct DNA methylation profile (n = 51, ASTRO PNC). Misinterpretation as carcinoma metastasis was common, since GFAP expression was absent in the primitive neuronal component, whereas TTF-1 expression was detected in 15/19 cases (79%) based on immunohistochemistry. Apart from mutations in IDH1, TP53, and ATRX, we observed enrichment for alterations in RB1 (n = 19/51, 37%) and MYCN (n = 14/51, 27%). Homozygous CDKN2A/B deletion (n = 1/51, 2%) and CDK4 amplification (n = 3/51, 6%) were relatively rare events. Clinical (n = 31 patients) and survival data (n = 23 patients) indicate a clinical behaviour similar to other CNS WHO grade 4 IDH-mutant astrocytomas, however with an increased risk for leptomeningeal (n = 7) and extra-axial (n = 2) spread. Taken together, ASTRO PNC is defined by a distinct molecular and histological appearance that can mimic metastatic disease and typically follows an aggressive clinical course.

Keywords: MYCN; RB1; Astrocytoma; DNA methylation; IDH-mutant; Primitive neuronal component.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: MS is scientific advisor and shareholder of Heidelberg Epignostix and Halo Dx, and a scientific advisor of Arima Genomics, and InnoSIGN, and received research funding from Lilly USA, and Illumina USA. DC, SMP, DS, AvD and FS are shareholders of Heidelberg Epignostix. Ethical approval: Collection and analysis of corresponding tissue samples and clinical data was performed in accordance with local ethics regulations (local ethics vote S-318/2022) and in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Figures

Fig. 1
Fig. 1
a The index case presents itself with a small blue round cell morphology with mitotic figures and occasional cell wrapping. b TTF-1 immunohistochemistry is expressed in the tumour cells. c High-molecular-weight cytokeratins were not expressed. d Synaptophysin is expressed. Scale bar denotes 200 µm
Fig. 2
Fig. 2
Methylation data: in a tSNE analysis with selected reference entities from our database (n = 310), astrocytoma, IDH-mutant, PNC separates clearly from the other entities. PMMRDIA, primary mismatch-repair-deficient IDH-mutant astrocytoma; MB SHH IDH, medulloblastoma, SHH-activated, IDH-mutant; GBM PNC, glioblastoma, IDH-wildtype, with primitive neuronal component. The methylation class astrocytoma, IDH-mutant, high grade consists of 28 grade 4 tumours and 3 grade 3 tumours. The methylation class astrocytoma, IDH-mutant, low grade consists of 2 grade 4 tumours, 13 grade 3 tumours and 17 grade 2 tumours
Fig. 3
Fig. 3
a All cases investigated by histology harbour a primitive neuronal component with small blue round tumour cells. In addition, in this case, cell wrapping (arrow) can be observed. b In most cases, a sharp demarcation of the primitive neuronal component and the astrocytic component can be found. c Presence of tumour growth inside the lumina of two vessels (asterisks). Despite reported extra-axial spread in this tumour entity, this case does not have reported metastases: d some cases present themselves with rosettes (arrows). Scale bar denotes 60 µm in a, b and d. Scale bar denotes 600 µm in c
Fig. 4
Fig. 4
a TTF-1: the primitive neuronal component expresses TTF-1 (using TTF-1 clone EP229). In a subset of cases, the expression is limited to a small number of cells. b IDH1 R132H: most tumour cases strongly express IDH1 R132H. c ATRX: nuclear ATRX expression is lost in most of the cases with blood vessels suited as positive internal controls. d GFAP: GFAP expression is lost in the primitive neuronal component. e Olig2: a subset of the primitive tumour cells expresses Olig2. f AE1/3: the tumours do not express high-molecular-weight cytokeratins stained with AE1 and/or AE3. g Ki-67: the proliferation index is high in the primitive neuronal component, whilst in most cases, the glial component does not show an elevated proliferation index. h p53: p53 is strongly expressed in the primitive tumour cells. i Synaptophysin: synaptophysin is expressed in the primitive tumour cells. Scale bar denotes 300 µm
Fig. 5
Fig. 5
a Oncoprint of 21 samples for which DNA targeted panel sequencing was performed, including genetic mutations, immunohistochemistry (IHC) and copy number variations calculated from the DNA methylation array. b The copy number summary plot (n = 42) reveals a focal deletion at the RB1 locus in addition to several chromosomal gains and losses
Fig. 6
Fig. 6
a Left side: the most common site of origin for primary diagnoses of ASTRO PNC is the frontal lobe followed by the temporal lobe. Right side: for recurrent ASTRO PNC cases, the most common site is the temporal lobe. b The tumours show a predisposition for the male sex. c Age distribution in ASTRO PNC (n = 30, median age = 38). d Kaplan–Meier estimate indicates no significant difference to IDH-mutant astrocytomas WHO grade 4 (p = 0.24). In contrast, there is a significant difference to IDH-mutant astrocytomas WHO grade 2 and 3 (p(A2) = < 0.0001; p(A3) = < 0.0001)

References

    1. Balanis NG, Sheu KM, Esedebe FN, Patel SJ, Smith BA, Park JW et al (2019) Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies. Cancer Cell 36(17–34):e17. 10.1016/j.ccell.2019.06.005 - PMC - PubMed
    1. Banan R, Stichel D, Bleck A, Hong B, Lehmann U, Suwala A et al (2020) Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol 140:569–581. 10.1007/s00401-020-02194-y - PubMed
    1. Bingle CD (1997) Thyroid transcription factor-1. Int J Biochem Cell Biol 29:1471–1473. 10.1016/s1357-2725(97)00007-1 - PubMed
    1. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608. 10.1007/s00401-020-02127-9 - PMC - PubMed
    1. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. 10.1038/nature26000 - PMC - PubMed

Publication types

Substances